

Jitka Palich Fučková

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6426228/publications.pdf>

Version: 2024-02-01

57
papers

6,540
citations

136950

32
h-index

182427

51
g-index

58
all docs

58
docs citations

58
times ranked

8650
citing authors

#	ARTICLE	IF	CITATIONS
1	Safety and efficacy of dendritic cell-based immunotherapy DCVAC/OvCa added to first-line chemotherapy (carboplatin plus paclitaxel) for epithelial ovarian cancer: a phase 2, open-label, multicenter, randomized trial. , 2022, 10, e003190.		16
2	Immunological control of ovarian carcinoma by chemotherapy and targeted anticancer agents. Trends in Cancer, 2022, 8, 426-444.	7.4	13
3	An Autologous Dendritic Cell Vaccine Promotes Anticancer Immunity in Patients with Ovarian Cancer with Low Mutational Burden and Cold Tumors. Clinical Cancer Research, 2022, 28, 3053-3065.	7.0	26
4	Trial watch: Dendritic cell (DC)-based immunotherapy for cancer. OncoImmunology, 2022, 11, .	4.6	54
5	Calreticulin and cancer. Cell Research, 2021, 31, 5-16.	12.0	174
6	LTX-315-enabled, radiotherapy-boosted immunotherapeutic control of breast cancer by NK cells. OncoImmunology, 2021, 10, 1962592.	4.6	30
7	TIM-3 levels correlate with enhanced NK cell cytotoxicity and improved clinical outcome in AML patients. OncoImmunology, 2021, 10, 1889822.	4.6	21
8	Polymer-ritonavir derivate nanomedicine with pH-sensitive activation possesses potent anti-tumor activity in vivo via inhibition of proteasome and STAT3 signaling. Journal of Controlled Release, 2021, 332, 563-580.	9.9	11
9	Immunological configuration of ovarian carcinoma: features and impact on disease outcome. , 2021, 9, e002873.		30
10	Calreticulin arms NK cells against leukemia. OncoImmunology, 2020, 9, 1671763.	4.6	16
11	Assessment of NK cell-mediated cytotoxicity by flow cytometry after rapid, high-yield isolation from peripheral blood. Methods in Enzymology, 2020, 631, 277-287.	1.0	0
12	Methods to assess DC-dependent priming of T cell responses by dying cells. Methods in Enzymology, 2020, 632, 55-65.	1.0	1
13	Detection of immunogenic cell death and its relevance for cancer therapy. Cell Death and Disease, 2020, 11, 1013.	6.3	466
14	Immunoprophylactic and immunotherapeutic control of hormone receptor-positive breast cancer. Nature Communications, 2020, 11, 3819.	12.8	71
15	Converging focal radiation and immunotherapy in a preclinical model of triple negative breast cancer: contribution of VISTA blockade. OncoImmunology, 2020, 9, 1830524.	4.6	34
16	M2-like macrophages dictate clinically relevant immunosuppression in metastatic ovarian cancer. , 2020, 8, e000979.		60
17	Trial watch: chemotherapy-induced immunogenic cell death in immuno-oncology. OncoImmunology, 2020, 9, 1703449.	4.6	156
18	Side-by-side comparison of flow cytometry and immunohistochemistry for detection of calreticulin exposure in the course of immunogenic cell death. Methods in Enzymology, 2020, 632, 15-25.	1.0	3

#	ARTICLE	IF	CITATIONS
19	Consensus guidelines for the definition, detection and interpretation of immunogenic cell death. , 2020, 8, e000337.		610
20	Calreticulin exposure on malignant blasts correlates with improved natural killer cell-mediated cytotoxicity in acute myeloid leukemia patients. Haematologica, 2020, 105, 1868-1878.	3.5	32
21	TIM-3 Dictates Functional Orientation of the Immune Infiltrate in Ovarian Cancer. Clinical Cancer Research, 2019, 25, 4820-4831.	7.0	71
22	Induction of Tolerance and Immunity by Dendritic Cells: Mechanisms and Clinical Applications. Frontiers in Immunology, 2019, 10, 2393.	4.8	92
23	Calreticulin exposure correlates with robust adaptive antitumor immunity and favorable prognosis in ovarian carcinoma patients. , 2019, 7, 312.		52
24	Phase I/II trial of dendritic cell-based active cellular immunotherapy with DCVAC/PCa in patients with rising PSA after primary prostatectomy or salvage radiotherapy for the treatment of prostate cancer. Cancer Immunology, Immunotherapy, 2018, 67, 89-100.	4.2	36
25	Relevance of the chaperone-like protein calreticulin for the biological behavior and clinical outcome of cancer. Immunology Letters, 2018, 193, 25-34.	2.5	36
26	Mature dendritic cells correlate with favorable immune infiltrate and improved prognosis in ovarian carcinoma patients. , 2018, 6, 139.		131
27	RNA-seq of macrophages of amoeboid or mesenchymal migratory phenotype due to specific structure of environment. Scientific Data, 2018, 5, 180198.	5.3	13
28	Dendritic cells pulsed with tumor cells killed by high hydrostatic pressure inhibit prostate tumor growth in TRAMP mice. OncoImmunology, 2017, 6, e1362528.	4.6	15
29	Trial watch: Immune checkpoint blockers for cancer therapy. OncoImmunology, 2017, 6, e1373237.	4.6	62
30	Caspase-2 and oxidative stress underlie the immunogenic potential of high hydrostatic pressure-induced cancer cell death. OncoImmunology, 2017, 6, e1258505.	4.6	30
31	Calreticulin exposure by malignant blasts correlates with robust anticancer immunity and improved clinical outcome in AML patients. Blood, 2016, 128, 3113-3124.	1.4	107
32	Dendritic cells pulsed with tumor cells killed by high hydrostatic pressure induce strong immune responses and display therapeutic effects both in murine TC-1 and TRAMP-C2 tumors when combined with docetaxel chemotherapy. International Journal of Oncology, 2016, 48, 953-964.	3.3	33
33	Trial Watch: Immunotherapy plus radiation therapy for oncological indications. OncoImmunology, 2016, 5, e1214790.	4.6	64
34	Trial Watch“Immunistimulation with cytokines in cancer therapy. OncoImmunology, 2016, 5, e1115942.	4.6	52
35	Calreticulin Expression in Human Non“Small Cell Lung Cancers Correlates with Increased Accumulation of Antitumor Immune Cells and Favorable Prognosis. Cancer Research, 2016, 76, 1746-1756.	0.9	164
36	Trial Watch“Oncolytic viruses and cancer therapy. OncoImmunology, 2016, 5, e1117740.	4.6	88

#	ARTICLE	IF	CITATIONS
37	Trial Watch: Small molecules targeting the immunological tumor microenvironment for cancer therapy. <i>Oncolmmunology</i> , 2016, 5, e1149674.	4.6	46
38	Trial Watch: Immunostimulation with Toll-like receptor agonists in cancer therapy. <i>Oncolmmunology</i> , 2016, 5, e1088631.	4.6	104
39	Prognostic and Predictive Value of DAMPs and DAMP-Associated Processes in Cancer. <i>Frontiers in Immunology</i> , 2015, 6, 402.	4.8	135
40	Molecular and Translational Classifications of DAMPs in Immunogenic Cell Death. <i>Frontiers in Immunology</i> , 2015, 6, 588.	4.8	317
41	Combinatorial Strategies for the Induction of Immunogenic Cell Death. <i>Frontiers in Immunology</i> , 2015, 6, 187.	4.8	289
42	Distinct patterns of intratumoral immune cell infiltrates in patients with HPV-associated compared to non-virally induced head and neck squamous cell carcinoma. <i>Oncolmmunology</i> , 2015, 4, e965570.	4.6	189
43	Trial Watch: Immunomodulatory monoclonal antibodies for oncological indications. <i>Oncolmmunology</i> , 2015, 4, e1008814.	4.6	102
44	Trial Watch: Immunogenic cell death inducers for anticancer chemotherapy. <i>Oncolmmunology</i> , 2015, 4, e1008866.	4.6	237
45	Trial Watch: Adoptive cell transfer for oncological indications. <i>Oncolmmunology</i> , 2015, 4, e1046673.	4.6	29
46	Trial watch: Naked and vectored DNA-based anticancer vaccines. <i>Oncolmmunology</i> , 2015, 4, e1026531.	4.6	26
47	Phase I/II clinical trial of dendritic-cell based immunotherapy (DCVAC/PCa) combined with chemotherapy in patients with metastatic, castration-resistant prostate cancer. <i>Oncotarget</i> , 2015, 6, 18192-18205.	1.8	111
48	Classification of current anticancer immunotherapies. <i>Oncotarget</i> , 2014, 5, 12472-12508.	1.8	395
49	Consensus guidelines for the detection of immunogenic cell death. <i>Oncolmmunology</i> , 2014, 3, e955691.	4.6	686
50	Physical modalities inducing immunogenic tumor cell death for cancer immunotherapy. <i>Oncolmmunology</i> , 2014, 3, e968434.	4.6	160
51	High hydrostatic pressure induces immunogenic cell death in human tumor cells. <i>International Journal of Cancer</i> , 2014, 135, 1165-1177.	5.1	151
52	Day 3 Poly (I:C)-activated dendritic cells generated in CellGro for use in cancer immunotherapy trials are fully comparable to standard Day 5 DCs. <i>Immunology Letters</i> , 2014, 160, 39-49.	2.5	8
53	Dynamics of T cell infiltration during the course of ovarian cancer: The gradual shift from a Th17 effector cell response to a predominant infiltration by regulatory T cells. <i>International Journal of Cancer</i> , 2013, 132, 1070-1079.	5.1	89
54	Trial watch. <i>Oncolmmunology</i> , 2013, 2, e25771.	4.6	150

#	ARTICLE	IF	CITATIONS
55	Poly I: C-activated dendritic cells that were generated in CellGro for use in cancer immunotherapy trials. <i>Journal of Translational Medicine</i> , 2011, 9, 223.	4.4	38
56	Human Tumor Cells Killed by Anthracyclines Induce a Tumor-Specific Immune Response. <i>Cancer Research</i> , 2011, 71, 4821-4833.	0.9	355
57	FOCUS on FOCIS: Combined chemo-immunotherapy for the treatment of hormone-refractory metastatic prostate cancer. <i>Clinical Immunology</i> , 2009, 131, 1-10.	3.2	36